Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Other Accumulated Expenses (2018 - 2025)

China SXT Pharmaceuticals has reported Other Accumulated Expenses over the past 8 years, most recently at $674391.0 for Q1 2025.

  • For Q1 2025, Other Accumulated Expenses rose 86.53% year-over-year to $674391.0; the TTM value through Mar 2025 reached $674391.0, up 86.53%, while the annual FY2025 figure was $674391.0, 86.53% up from the prior year.
  • Other Accumulated Expenses for Q1 2025 was $674391.0 at China SXT Pharmaceuticals, up from $361543.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $1.2 million in Q1 2022 and troughed at $361543.0 in Q1 2024.
  • A 5-year average of $761430.6 and a median of $789232.0 in 2023 define the central range for Other Accumulated Expenses.
  • Biggest five-year swings in Other Accumulated Expenses: soared 184.9% in 2021 and later crashed 54.19% in 2024.
  • Year by year, Other Accumulated Expenses stood at $819677.0 in 2021, then skyrocketed by 41.8% to $1.2 million in 2022, then crashed by 32.1% to $789232.0 in 2023, then crashed by 54.19% to $361543.0 in 2024, then soared by 86.53% to $674391.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for SXTC at $674391.0 in Q1 2025, $361543.0 in Q1 2024, and $789232.0 in Q1 2023.